{"schema_version":"1.0","type":"article","title":"減肥成王：GLP-1 正在把全球生技資本重新洗牌","url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.md","lang":"zh-Hant","date":"2026-06-11","publish_at":"2026-06-11T08:00:01+08:00","updated_at":"2026-06-11","category":"商業分析系列","topic":"生技估值","tags":["GLP-1","減肥藥","生技資本","腫瘤管線","BD","代謝疾病"],"summary":"GLP-1 不只是減重藥題材，而是重新配置全球藥廠研發預算、產能投資、BD 談判與生技估值規則的核心變數。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"GLP-1 抽走生技資本注意力，重新改寫腫瘤與代謝賽道的資源配置。","url":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-01.png"},{"alt":"藥時事與 CMoney 全曜財經共同打造減肥藥賽道投資課程。","url":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-02.jpg"},{"alt":"晚期研發報酬率回升背後，肥胖症資產成為大型藥廠管線價值的重要來源。","url":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-03.png"},{"alt":"GLP-1 不只是減重題材，而是牽動產能、BD、估值與資本配置的產業變數。","url":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/cover-glp1-capital.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-11）。減肥成王：GLP-1 正在把全球生技資本重新洗牌。https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-11-glp1-biotech-capital-reshuffle-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}